Abstract
Contralateral prophylactic mastectomy (CPM) refers to removal of the opposite uninvolved breast in women with unilateral breast cancer, and rates are increasing worldwide. In observational studies, CPM is often associated with reductions in breast cancer-specific and all-cause mortality when compared to unilateral surgical treatment alone, but this may reflect selection of a healthier cohort for CPM (selection bias). To further explore this possibility, we examined the association between CPM and non-cancer mortality, an indicator of selection bias. We identified 449,178 adult women diagnosed with unilateral, primary American Joint Committee on Cancer (AJCC) stage I–III ductal or lobular breast cancer, utilizing the 1998–2010 Surveillance, Epidemiology, and End Results dataset. Of these, 5.8 % (n = 25,961) underwent CPM as their first course of treatment. We examined associations between CPM and breast cancer-specific, all-cause, and non-cancer mortality utilizing multivariate logistic regression, adjusting for age, race, AJCC stage, estrogen receptor status, progesterone receptor status, and histologic grade of the tumor. Among all patients receiving CPM as first course of treatment, CPM was associated with lower breast cancer-specific [HR 0.84 (95 % CI 0.79–0.89)], all-cause [HR 0.83 (95 % CI 0.80–0.88)], and non-cancer [HR 0.71 (95 % CI 0.64–0.80)] 5-year hazard of death. Although our results are consistent with other observational studies showing associations between CPM and reductions in breast cancer-specific and all-cause mortality, we demonstrate an even stronger association between CPM and reduced non-cancer mortality. Thus, the reported associations between CPM and reductions in mortality might at least partly be attributable to selection bias.
Similar content being viewed by others
References
Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 312(9):902–914
Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209
Neuburger J, Macneill F, Jeevan R, van der Meulen JH, Cromwell DA (2013) Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. BMJ Open 3(8). doi:10.1136/bmjopen-2013-003179
Musiello T, Bornhammar E, Saunders C (2013) Breast surgeons’ perceptions and attitudes towards contralateral prophylactic mastectomy. ANZ J Surg 83(7–8):527–532
Sim Y, Tan VK, Ho GH, Wong CY, Madhukumar P, Tan BK et al (2014) Contralateral prophylactic mastectomy in an Asian population: a single institution review. Breast 23(1):56–62
Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol 17(10):2554–2562
Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180(6):439–445
Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19):4275–4286
Bedrosian I, Hu CY, Chang GJ (2010) Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401–409
Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17(10):2702–2709
Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB et al (2012) Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637–5643
Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I et al (2013) Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 140(1):135–142
Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N et al (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226
Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359(9302):248–252
Institute nc. surveillance epidemiology and end results program (2014) Available from: http://seer.cancer.gov/. Accessed 29 April 2014
Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S et al (2001) Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 67(1):1–8
Narod SA (2014) Bilateral breast cancers. Nat Rev Clin Oncol 11(3):157–166
Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206(5):704–708
Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14(7):e262–e269
Jatoi I, Benson JR, Liau SS, Chen Y, Cisco RM, Norton JA et al (2010) The role of surgery in cancer prevention. Curr Probl Surg 47(10):750–830
King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29(16):2158–2164
Katz SJ, Morrow M (2013) Contralateral prophylactic mastectomy for breast cancer: addressing peace of mind. JAMA 310(8):793–794
Jatoi I, Benson JR (2013) The case against routine preoperative breast MRI. Future Oncol 9(3):347–353
Sorbero ME, Dick AW, Beckjord EB, Ahrendt G (2009) Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 16(6):1597–1605
Khan SA (2011) Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol 29(16):2132–2135
Jatoi I, Benson JR (2014) Novel approaches to the diagnosis and treatment of breast cancer. Future Oncol 10(4):515–518
Grimes DA, Schulz KF (2012) False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol 120(4):920–927
Sackett DL (1979) Bias in analytic research. J Chronic Dis 32(1–2):51–63
Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC et al (2005) Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330(7497):960–962
Funding
Dr. Parsons is supported by grant K07CA175063 from the U.S. National Cancer Institute.
Conflict of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jatoi, I., Parsons, H.M. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias. Breast Cancer Res Treat 148, 389–396 (2014). https://doi.org/10.1007/s10549-014-3160-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-014-3160-y